EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis

Francesco Passamonti iD, Youbei Lou, Manoj Chevli, Pranav Abraham

Future Oncology · 2024

DOI: 10.2217/fon-2022-1256 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Future Oncology, 2024. Verfasst von Francesco Passamonti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Milano, 20…. Hauptthemen laut MEDLINE: Nitriles, Pyrimidines, Pyrazoles, Primary Myelofibrosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb, Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Fedratinib is an oral selective JAK2 inhibitor approved in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF).

Methods

This observational study assessed adult US patients who received ruxolitinib for primary MF (Flatiron Health database: 1 January 2011-31 October 2020). Patients were stratified by post-ruxolitinib treatment (fedratinib vs non-fedratinib).

Results

Characteristics were comparable between fedratinib (n=70) and non-fedratinib (n=159) groups (median age: 71.0 vs 70.0 years; females: 55.7 vs 50.3%; median follow-up: 7.0 vs 6.0 months). Median overall survival (not reached vs 17 months) and 12 month survival (71.6 vs 53.5%) were improved with fedratinib versus the non-fedratinib therapies.

Conclusion

In MF patients who received frontline ruxolitinib, survival was improved with subsequent fedratinib versus non-fedratinib care. Real-world outcomes show that in patients with primary myelofibrosis in the US, who received frontline ruxolitinib, survival was improved with subsequent fedratinib, an oral selective JAK2 inhibitor, versus non-fedratinib care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NitrilesPyrimidinesPyrazolesPrimary MyelofibrosisPyrrolidinesJanus Kinase 2SulfonamidesHumansFemaleMaleAgedMiddle AgedAged, 80 and overTreatment OutcomeRetrospective StudiesProtein Kinase InhibitorsBenzenesulfonamides

Stichwörter der Autor:innen

fedratinibmyelofibrosisoverall survivalreal-world outcomesruxolitinib

Substanzen

ruxolitinibNitrilesPyrimidinesPyrazolesfedratinibPyrrolidinesJanus Kinase 2SulfonamidesJAK2 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Milano, 20122, Italy.
  • Bristol Myers Squibb, 3551 Lawrenceville, NJ 08648, USA.
  • Bristol Myers Squibb, Denham, Uxbridge, UB8 1DH, UK.

ORCID-Profile: Francesco Passamonti

Förderung

  • Bristol-Myers Squibb
  • Bristol Myers Squibb

Zitieren

APA

Passamonti, F., Lou, Y., Chevli, M., & Abraham, P. (2024). Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis. Future Oncology. https://doi.org/10.2217/fon-2022-1256

Vancouver

Passamonti F, Lou Y, Chevli M, Abraham P. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis. Future Oncology. 2024. doi:10.2217/fon-2022-1256

BibTeX
@article{Passamonti2024,
  author = {Passamonti, Francesco and Lou, Youbei and Chevli, Manoj and Abraham, Pranav},
  title = {Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis},
  journal = {Future Oncology},
  year = {2024},
  doi = {10.2217/fon-2022-1256}
}
Kostenlos starten →